drugset / Trial / NCT01995656

A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes

NCT01995656 ↗

Phase 1 Completed 44 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3108743 in healthy participants and in participants with type 2 diabetes. The study will also investigate how LY3108743 affects the levels of blood sugar and other naturally occurring substances (e.g. hormones that control the way sugar is used) in the body, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it. Information about any side effects that may occur will be collected. The study is expected to last approximately 7 to 8 weeks for each participant. The study will have up to 3 parts. Participants may enroll in only one part.

Timeline

Start
2013-12
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3108743 Unknown — Oral